STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against Ultragenyx Pharmaceutical Inc. (RARE)

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. on behalf of investors who purchased its common stock during the specified class period, alleging misleading statements regarding clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Ultragenyx shares from August 3, 2023, to December 26, 2025 [1][2]. - Investors have until April 6, 2026, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Allegations - The complaint claims that Ultragenyx misled investors by raising expectations about the ORBIT and COSMIC studies, which tested setrusumab for Osteogenesis Imperfecta, while concealing that neither study significantly reduced clinical fracture rates compared to control groups [3]. - Following the disclosure of the study results, Ultragenyx's share price fell from $34.19 on December 26, 2025, to $19.72 on December 29, 2025, representing a decline of over 42% in a single day [3]. Group 3: Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, focusing on treatments for rare diseases [2].